Brief: Santen Announces Initiation Of Phase 3 Clinical Development Program

SANTEN PHARMACEUTICAL

22/10/2018 13:34

Oct 22 (Reuters) - Santen Pharmaceutical Co Ltd  4536.T :
    * SANTEN ANNOUNCES INITIATION OF PHASE 3 CLINICAL
DEVELOPMENT
PROGRAM (SPECTRUM) IN THE UNITED STATES EVALUATING OMIDENEPAG
ISOPROPYL (DE-117) FOR THE TREATMENT OF GLAUCOMA OR OCULAR
HYPERTENSION

Source text for Eikon:  ID:nPnbNdnSna 
Further company coverage:  4536.T 

 ((Reuters.Briefs@thomsonreuters.com;))